Vitrolife is acquiring 25% of the shares of HertART, with an option to acquire up to 100%. The purchase sum amounts to DKK 2m. For the Vitrolife Group as a whole, the acquisition will initially have a marginal effect on income and sales.

Tony Winslof, head of business development at Vitrolife, said: “The collaboration will mainly concern products for in vitro fertilization but is of fundamental importance as there are points of contact primarily in the stem cell business area.

“We see the collaboration with HertART as an opportunity to fill our research and development portfolio more quickly within the framework of our long-term development objectives.”

HertART works with registered products within In Vitro Fertilization (IVF)/Assisted Reproductive Technologies (ART).